This site is intended for healthcare professionals
CSU Learning Zone

eLearning modules

Read time: 180 mins
Published:18th Aug 2020
Discover how recent breakthroughs in our understanding of the anti-IgE pathway in CSU might influence the management of this disease and improve your patient outcomes in the future.

Are you up-to-date with the latest guidelines and treatments available? Put your knowledge to the test with these three interactive eLearning modules. Familiarise yourself with the most recent advances in our understanding of chronic spontaneous urticaria (CSU) which includes the identification of two distinct endotypes of CSU and how the ongoing development of novel treatment options might impact your clinical practice in the future.

Closing questions Test your knowledge 5 mins
Introduction Introduction to the eLearning module 5 mins
Section 1 Meet the experts 5 mins
Section 2 Background 5 mins
Section 3 Mast cell activation 10 mins
Section 4 IgE receptors 10 mins
Section 5 IgE inhibitors 10 mins
Section 6 Summary 2 mins

Course overview

On completion of this module participants should have a good understanding of:

  • the role of mast cells and their mediators in CSU pathogenesis
  • the differences between type I and type IIb autoimmunity
  • the differences between the IgE receptors FcεRI and CD23
  • how anti-IgE therapies can be used to treat CSU

Evaluation questions will be asked at the end of the module. You must achieve a score of 60% or above to pass.

Creation of this eLearning module was funded by Novartis Pharma AG in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. Novartis Pharma AG were given the opportunity to review the content and make suggestions.

System Requirements

Faculty

Professor Marcus Maurer. Professor of Dermatology and Allergy at the Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany. He is also the Director of Research at the Department of Dermatology and Allergy, Associate Director of the Allergie-Centrum-Charité, and Head of the Specialty Clinics for angioedema, hereditary angioedema, urticaria, mastocytosis, pruritus, auto-inflammatory disorders and the Dermatological Allergology Laboratory.

Dr Alexander Eggel. Principal investigator at the Department of Rheumatology, Immunology and Allergy at the University of Bern, Switzlerland. His major research interests include the biological mechanisms underlying both beneficial and pathologic type 2 immune responses.

Closing questions Test your knowledge 5 mins
Introduction Introduction to the eLearning module 5 mins
Section 1 Meet the experts 2 mins
Section 2 The burden of CSU 5 mins
Section 3 Management of CSU 5 mins
Section 4 Unmet needs in CSU 10 mins
Section 5 Anti-IgE therapy 5 mins
Section 6 The benefits of current and future anti IgEs 10 mins
Section 7 Summary 2 mins

Course overview

On completion of this module participants should have a good understanding of:

  • the humanistic and economic burden of CSU
  • current EACCI/GA2LEN/EDF/WAO guidelines for the management of CSU
  • the limitations of currently available therapies
  • the benefits of current and future anti-IgE therapies

Evaluation questions will be asked at the end of the module. You must achieve a score of 60% or above to pass.

Creation of this eLearning module was funded by Novartis Pharma AG in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. Novartis Pharma AG were given the opportunity to review the content and make suggestions.

System Requirements

Faculty

Professor Marcus Maurer. Professor of Dermatology and Allergy at the Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany. He is also the Director of Research at the Department of Dermatology and Allergy, Associate Director of the Allergie-Centrum-Charité, and Head of the Specialty Clinics for angioedema, hereditary angioedema, urticaria, mastocytosis, pruritus, auto-inflammatory disorders and the Dermatological Allergology Laboratory.

Closing questions Test your knowledge 5 mins
Introduction Introduction to the eLearning module 5 mins

1

Diagnosing and assessing your patients with CSU

10 mins

2

First- and second-line therapy for CSU

10 mins

3

Third-line therapy for CSU

10 mins

4

Relapse and retreatment

10 mins

Course overview

How do you manage patients with chronic spontaneous urticaria (CSU)? How does it compare to your peers around the world? Is it aligned with the latest international guidelines?

Take this interactive eLearning module and explore the most recent EAACI/GA2LEN/EDF/WAO urticaria guidelines with expert insights from the panel at the epgonline.org (now medthority.com) EAACI 2018 satellite symposium. Complete the interactive questions and discover how your practice compares to your peers in your region and around the world.

This eLearning contains new materials as well as content from the EAACI 2018 satellite symposium.

Creation of this eLearning module was funded by an educational grant from Novartis, who were given the opportunity to review the content for medical accuracy only.

This module consists of four sections containing interactive questions as well as a final evaluation module where you can test your learning.

System Requirements

Faculty

Marcus Maurer, Désirée Larenas-Linnemann, Elias Toubi, Zuatao Zhao.

Welcome: